In addition, the ALK fusion genes have been identified as tumor driver genes and potential therapeutic targets, and targeted therapy with ALK inhibitors, such as lorlatinib and alectinib, exhibited favorable antitumor activity in IMTUB with ALK fusion (13, 14). Here, ALK is linked to neoplasm.